Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cumberland Pharmaceuticals

3.44
-0.0100-0.29%
Post-market: 3.440.00000.00%18:19 EDT
Volume:13.63K
Turnover:47.44K
Market Cap:51.46M
PE:-16.35
High:3.56
Open:3.45
Low:3.37
Close:3.45
52wk High:7.25
52wk Low:1.04
Shares:14.96M
Float Shares:7.97M
Volume Ratio:0.48
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2104
EPS(LYR):-0.4609
ROE:-10.89%
ROA:-2.55%
PB:1.84
PE(LYR):-7.46

Loading ...

Hochtief AG Turner Opens 284 Million Peabody Union Mixed Use Development in Nashville

Reuters
·
Oct 15

Cumberland adds Vibativ to national group purchasing agreement with Premier

TIPRANKS
·
Oct 13

Cumberland Pharmaceuticals' Vibativ® Added to National Group Purchasing Agreement With Premier, Inc.

THOMSON REUTERS
·
Oct 13

BRIEF-Cumberland Pharmaceuticals Ibuprofen Injection Product Approved In Mexico

Reuters
·
Oct 01

Cumberland Pharmaceuticals Inc - Ibuprofen Injection Product Approved in Mexico

THOMSON REUTERS
·
Oct 01

Cumberland Pharmaceuticals and Tabuk Announce Agreement to Launch Vibativ® in Saudi Arabia and Middle East

Reuters
·
Sep 29

A.J. Kazimi, Chairman and CEO, Reports Acquisition of Common Shares in Cumberland Pharmaceuticals Inc

Reuters
·
Sep 12

Director Kenneth Krogulski Reports Acquisition of Common Shares in Cumberland Pharmaceuticals Inc

Reuters
·
Aug 11

Cumberland Pharma's Q2 revenue rises 10% yr/yr

Reuters
·
Aug 06

Cumberland Q2 Adj. EPS $0.18 Up From $0.01 YoY, Sales $10.800M Up From $9.849M YoY

Benzinga
·
Aug 06

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

THOMSON REUTERS
·
Aug 06

Cumberland Pharmaceuticals Q2 Adjusted EPS USD 0.02

THOMSON REUTERS
·
Aug 06

Cumberland Pharmaceuticals Q2 EPS USD -0.05

THOMSON REUTERS
·
Aug 06

Cumberland Pharmaceuticals Secures Vizient Contract for Vibativ 4-Vial Starter Pak

Reuters
·
Aug 04

Cumberland Pharmaceuticals Receives Vizient Contract for New Vibativ® 4-Vial Starter Pak

THOMSON REUTERS
·
Aug 04

Kenneth Krogulski, Director, Reports Acquisition of Common Shares in Cumberland Pharmaceuticals Inc

Reuters
·
Jul 12

Cumberland Pharmaceuticals Unveils Promising Phase 2 Trial Results for Ifetroban in Treating Duchenne Muscular Dystrophy Heart Disease

Reuters
·
Jun 23

A.J. Kazimi, Chairman and CEO, Reports Acquisition of Common Shares in Cumberland Pharmaceuticals Inc

Reuters
·
Jun 06

Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

Reuters
·
May 28

Cumberland, Qureight Collaborate on Lung Disease Treatment Trial

MT Newswires Live
·
May 14